A Combination of Two Currently Approved Drugs to Enhance the Treatment of Schizophrenia

This study has been completed.
Sponsor:
Information provided by:
Eli Lilly and Company
ClinicalTrials.gov Identifier:
NCT00089869
First received: August 16, 2004
Last updated: July 18, 2006
Last verified: July 2006
  Purpose

Study of a medication for the treatment of Schizophrenia in patients who are already taking Abilify, Risperdal, Seroquel, Zyprexa


Condition Intervention Phase
Schizophrenia
Drug: olanzapine
Drug: atomoxetine
Drug: placebo
Phase 1
Phase 2

Study Type: Interventional
Study Design: Primary Purpose: Treatment

Resource links provided by NLM:


Further study details as provided by Eli Lilly and Company:

  Eligibility

Ages Eligible for Study:   18 Years to 55 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Must have a clinical diagnosis of Schizophrenia
  • Must be at least 18 years of age and not older than 55 years of age
  • Must have been stable on a dose of Abilify, Risperdal, Seroquel, or Zyprexa for the past 8 weeks
  • Women of childbearing potential must be using a medically accepted means of contraception
  • Must be able to swallow capsules

Exclusion Criteria:

  • Has serious health problems other than Schizophrenia
  • Takes an antidepressant for depression
  • Takes insulin for diabetes
  • Have a history of alcohol or drug dependence (except for nicotine and caffeine) within the past 6 months
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00089869

Locations
United States, California
"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician."
Cerritos, California, United States
"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician.
Chula Vista, California, United States
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
Garden Grove, California, United States
"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician."
San Diego, California, United States
United States, Connecticut
"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician."
New Haven, Connecticut, United States
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
New Haven, Connecticut, United States
United States, Georgia
"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician."
Atlanta, Georgia, United States
United States, Illinois
"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician."
Chicago, Illinois, United States
United States, Indiana
"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician."
Indianapolis, Indiana, United States
United States, Iowa
"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician."
Iowa City, Iowa, United States
United States, Minnesota
"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician."
Minneapolis, Minnesota, United States
United States, New Hampshire
"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician."
Lebanon, New Hampshire, United States
United States, New York
"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician."
New York, New York, United States
United States, North Carolina
"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician."
Butner, North Carolina, United States
"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician."
Chapel Hill, North Carolina, United States
United States, Oklahoma
"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician."
Okalahoma City, Oklahoma, United States
United States, Texas
"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician."
Austin, Texas, United States
"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician."
Irvin, Texas, United States
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
Irving, Texas, United States
"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at (1-877-285-4559) or speak with your personal physician."
San Antonio, Texas, United States
Sponsors and Collaborators
Eli Lilly and Company
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00089869     History of Changes
Other Study ID Numbers: 8269, H6U-MC-HGLM
Study First Received: August 16, 2004
Last Updated: July 18, 2006
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Schizophrenia
Schizophrenia and Disorders with Psychotic Features
Mental Disorders

ClinicalTrials.gov processed this record on September 18, 2014